The overall objective was to explore if FGF21 could be used safely and efficaciously to treat common obesity-associated metabolic dyscrasias, utilizing a research colony of obese and overweight cats with similar insulin resistance and metabolic alterations. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.